Technical Advantage
High security
ZT carrier proteins can be completely degraded by proteases into natural amino acids.
Low immunogenicity
Derived from natural proteins in the human body, with low immunogenicity.
Low cost
Escherichia coli fermentation has high yield, simple purification process, and cost only 1/10-1/5 of other technologies.
Short R&D cycle
Molecular design is fast, simple to connect, can be expressed in large intestine, short fermentation cycle, and fast product iteration.
Flexible design
Having multiple connection sites, it is easy to design multi-target and multifunctional fusion proteins.
Wide range of applications
Suitable for peptides, proteins, or enzymes with molecular weights ranging from a few amino acids to hundreds of amino acids, with a wide range of applications.
Technical Principles
The short half-life of protein drugs is one of the main factors limiting their clinical application. UKLong technology significantly prolongs the retention time of drugs in the body by increasing the hydrodynamic radius of proteins through ZT technology, utilizing in vivo recycling mechanisms, or enhancing their resistance to degradation.
The platform has established a standardized process for long-acting molecular design, from target analysis, molecular construction, activity evaluation to pharmacokinetic research, achieving standardized, universal, low-cost, and high-efficiency drug development.
Application Achievements
The UKLong technology has been successfully applied to multiple under development varieties such as long-acting GLP-1 receptor agonists, long-acting insulin, and long-acting growth hormone. The long-acting GLP-1 receptor agonist has been administered once a week, with a half-life more than three times longer than the original product.
Long acting technology significantly reduces the frequency of patient injections, from once a day to once a week or even a month, greatly improving patient medication adherence and quality of life.